SB 241, 88th R.S. history

Help | Status


SB 241, 88th R.S.
Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.

Last action: Effective on . . . . . . . . . . . . . . .

Author: Charles Perry
Sponsor: James Talarico

Session Law Chapter:
Acts 2023, 88th R.S.,ch. 244, General and Special Laws of Texas

Signed legislation

Companion:

HB 2529 (Identical)

Bill Analyses:
Committee Report (TLC)
Committee Report (TLC)
Enrolled (Senate Research Center)
Introduced (Senate Research Center)
Committee Report (Senate Research Center)

Subjects:
DIABETES
HEALTH & HUMAN SERVICES COMMISSION
Health--Other Diseases & Medical Conditions
Insurance--Health & Accident
MEDICINE & PRESCRIPTION DRUGS

House Committee: Public Health (Stephanie Klick, Liz Campos, Nicole Collier, Jacey Jetton, Ann Johnson, Jolanda Jones, Venton Jones, Tom Oliverson, Four Price, Reggie Smith, Tony Tinderholt)
Minutes: May 3 2023
Senate Committee: Health & Human Services (Lois Kolkhorst, César Blanco, Bob Hall, Kelly Hancock, Bryan Hughes, Morgan LaMantia, Borris Miles, Charles Perry, Kevin Sparks)
Minutes: March 15 2023

Index to Sections Affected

Texas Legislature Online


The Legislative Archive System is a work in progress. Complete information is not available for all bills and all sessions. Visit the Legislative Archive System status page for details. Please contact the Legislative Reference Library at 512-463-1252 if you have any questions. Information on this website is provided as a public service by the Legislative Reference Library. The Legislative Reference Library makes no representation as to its completeness or accuracy and makes no warranty in regard to its use. Users assume all risk of reliance on the information included on this site.